Population
In vitro platelet aggregation and fibrinogen binding assays
Design
Preclinical
Authors
Loading...
Should not yet change antiplatelet practice; leaves open further preclinical development of selective GPIIb-IIIa inhibitors.
Novel 5,6-bicyclic derivatives demonstrate highly potent and selective in vitro inhibition of the GPIIb-IIIa fibrinogen receptor, suggesting potential as antiplatelet agents.
Su et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: